Close Menu

GenMark

The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.

The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.

GenMark got clearance for an assay to detect fungal pathogens from blood cultures of patients with suspected bloodstream infections, and it received clearance for a bacterial assay.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.

Walgreens, Laboratory Corporation of America, and Inland Empire Health Plan (IEHP) this week announced plans to open nine new LabCorp patient centers within Walgreens stores in the greater Riverside, California area.

Just five of the 28 firms in the 360Dx Index saw their share prices rise last month. Veracyte led the gainers, while Accelerate Dx had the sharpest decline.

Pages